Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma
Crossref DOI link: https://doi.org/10.1186/s12931-015-0243-1
Published Online: 2015-07-16
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Beeh, Kai-Michael
LaForce, Craig
Gahlemann, Martina
Wenz, Arne
Toorawa, Robert
Fležar, Matjaž
License valid from 2015-07-16
Article History
Received: 17 February 2015
Accepted: 24 June 2015
First Online: 16 July 2015